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Abstract
Background: Takotsubo cardiomyopathy (TC) is characterized by a transient decrease in ejection fraction and a
reversible left ventricular dysfunction. The pathophysiology of TC is not completely understood. Heterogeneous and
multifactorial mechanisms are involved: drugs, emotional and physical stress, genetic and hormonal factors.
Case presentation: A 17 year-old male with metastatic pancreatic adenocarcinoma, under chemotherapy
containing 5-fluorouracil, presented severe left ventricular dysfunction requiring mechanical ventilation and
inotropes administration. He completely recovered in 2 weeks.
Conclusion: To our knowledge this is the first report of transient form of ventricular dysfunction, mimicking TC, in
an adolescent. We believe that children and adolescents receiving 5-fluorouracil should be closely monitored and
referred for investigation if they develop cardiac symptoms.
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Background
Takotsubo cardiomyopathy is a reversible cardiomyop-
athy characterized by a transient decrease in ejection
fraction and a reversible left ventricular dysfunction. The
pathophysiology of TC is not completely understood.
Heterogeneous and multifactorial mechanisms are in-
volved: drugs, emotional and physical stress, genetic and
hormonal factors. TC is most often seen in elderly
women and has never been reported in an adolescent [1].
Case Presentation
A 17 year-old male was diagnosed with metastatic pancre-
atic adenocarcinoma and started on chemotherapy with
Oxaliplatin and Gemcitabine. He received the first two
courses without any complications. The chemotherapy
schedule was then modified to include FOLFIRINOX, on
the basis of published data regarding the superiority of this
drug combination compared to gemcitabine for the treat-
ment of advanced pancreatic carcinoma [2]. He then re-
ceived oxaliplatin, 85 mg/m2, followed by leucovorin,
400 mg/ m2, irinotecan, 180 mg/ m2 and 5-fluorouracil
(5-FU) at a dose of 400 mg/m2 by intravenous bolus,
followed by a continuous intravenous infusion of
2400 mg/m2 over a 46-hour period. Approximately 4 h
after the start of the first 5-FU infusion, the patient experi-
enced vomiting and chest pain as well as an altered level
of consciousness with extreme agitation. Progressive diur-
esis contraction was also recorded. Vital signs were: blood
pressure 112/87 mmHg, heart rate 134/min and regular.
Brain and thorax CT scans and abdominal x-ray were
normal. Monitoring of vital signs revealed a progressive
decrease of blood pressure down to 90/50 mmHg. Echo-
cardiography showed severe and diffuse LV hypokinesis
with an ejection fraction of 20 %. Moderate right ventricu-
lar hypokinesis and a 20 × 16 mm thrombus in the right
atrium were also revealed (Additional file 1: Clip 1).
Plasma level of B-type natriuretic peptide was 800 pg/ml
(normal value 0–100), while creatine kinase-MB, myoglo-
bin and troponin levels were normal. Seventy-two hours
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later troponin and myoglobin levels rose to 0.16 ng/ml
and 356 ng/ml respectively (normal values 0-0.10 and 0–
170 respectively).
The patient was then transferred to the intensive care
unit and placed on mechanical ventilation. Treatment with
milrinone 0.75 mcg/kg/min, dopamine 12 mcg/kg/min,
and epinephrine 0.05 mcg/kg/min was started together
with anticoagulation based on heparin 20 UI/kg/h.
Twenty-four hours later echocardiography showed no
improvement in LV systolic and diastolic function.
Levosimendan 0.1 mcg/kg/min and norepinephrine
0.06 mcg/kg/min were added while dosage of milri-
none was decreased to 0.5 mcg/kg/min. Dobutamine
and fenoldopam were also used. Vital signs improved
slowly and echocardiography showed a progressive
improvement in ventricular systolic and diastolic function
(Additional file 2: Clip 2) with complete recovery after
14 days (Additional file 3: Clip 3). Under anticoagulation
with low molecular weight heparin, the right atrial
thrombus disappeared after 3 months. The final diagnosis
was: reversible cardiomyopathy induced by 5-FU. Conse-
quently, the chemotherapy schedule was modified and
5-FU administration excluded.
Discussion
We report a case of reversible cardiomyopathy induced
by 5-FU. Takotsubo cardiomyopathy (TC), also known
as apical ballooning syndrome, is a quite new clinical en-
tity characterized by a transient decrease in ejection
fraction and a reversible LV dysfunction consisting of
dyskinesia involving the apical or midventricular seg-
ments. TC is most often seen in elderly women. In a re-
view of studies from 2000 to 2012, Bossone et al
reported that the age of patients affected by TC ranged
from 59 to 73 years [1]. The pathophysiology of TC has
not been fully identified. Heterogeneous and multifactor-
ial mechanisms are involved [3–7]. Emotional and phys-
ical stress may play a role by releasing circulating
catecholamines that have direct effects on the myocar-
dium. The mechanism underlying the association be-
tween sympathetic stimulation and myocardial stunning
is unknown. One possibility is ischemia resulting from
epicardial coronary arterial spasm. An alternative mech-
anism is microvascular spasm. Abnormal coronary flow
in the absence of obstructive disease has been reported
in patients with stress-related myocardial dysfunction. A
third possible mechanism of catecholamine-mediated
myocardial stunning is direct myocyte injury, through
cyclic AMP–mediated calcium overload or by producing
oxygen-derived free radicals [4]. Familial cases of TC
are also described, suggesting a genetic role in the
pathogenesis of this condition [5]. However, estrogen
deficiency may also be a risk factor in the develop-
ment of this type of reversible cardiomyopathy. This
deficiency could explain the high incidence in post-
menopausal women [6].
Several reports have discussed drugs that may cause
TC [3, 7]. Among these, 5-FU is described as a po-
tential cause. Cardiotoxicity is a well-known adverse
effect of 5-FU which occurs in 1.2 to 18 % of pa-
tients, but the mechanism involved is still not fully
understood [8, 9]. In recent years several cases of 5-
FU-induced Takotsubo-like syndrome have been re-
ported in the literature [10–12]. It has been hypothe-
sized that extreme sympathetic stimulation causing
coronary vasospasm may play a role in the develop-
ment of TC.
According to the reported cases, TC is often seen in
elderly women who frequently have histories of smoking,
alcohol abuse, anxiety states, and hyperlipidemia. Our
patient however, was an adolescent, with no previous
history of cardiac dysfunction or other reported risk
factors. He was under treatment for pancreatic adeno-
carcinoma with liver metastases and, 4 h after the start
of 5-FU infusion, he developed chest pain and an altered
level of consciousness, which are typical findings associ-
ated with TC. Echocardiography showed severe and dif-
fuse LV hypokinesis with an increased level of cardiac
enzyme B-Type natriuretic peptide, troponin and myo-
globin, leading us to hypothesize TC. To our knowledge
this is the first reported case of 5-FU- induced transient
form of ventricular dysfunction, mimicking TC, in an
adolescent. This is probably due to the fact that the
drugs recognized as possible triggers of TC are not cur-
rently used in pediatric and young populations affected
by cancer [3].
The chemotherapeutic agent 5-FU, by inhibiting
thymidylate synthase in malignant cells, disrupts DNA
synthesis and promotes cell death. It is currently used
as adjuvant chemotherapy for colorectal cancer and
frequently for the treatment of pancreatic, breast,
bladder, gastric, esophageal and prostate cancer [8].
These neoplasms rarely affect adolescents. In the
USA, the annual age-adjusted incidence rate for all
carcinomas in patients younger than 20 years is 1.4
per million. More specific figures for pancreatic can-
cers in this age group are unavailable [13]. The only
occasional use of 5-FU in the pediatric population
could explain the absence of reports of TC in this
age group. This is in fact the first observation of
Takotsubo-like syndrome, in an adolescent.
Conclusion
Although TC has only been reported in adults, chil-
dren and adolescents with cardiac symptoms during
chemotherapy with 5-fluorouracil should be closely
monitored and referred for further investigations if
there is suspicion of this condition. Prompt acute
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clinical assessment coupled with ECG recordings and
cardiac enzyme analysis should be performed if cardi-
otoxicity is suspected. Further studies are necessary to
be able to assess the real incidence of TC in the
pediatric population.
Additional files
Additional file 1: Clip 1. Exam performed on May 17th. Diffuse left
ventricular hypokinesia can be observed with apical dyskinesia and
dilation. (AVI 17411 kb)
Additional file 2: Clip 2. Exam performed on May 23rd. Improvement in
left ventricular function is observed, with mild diffuse hypokinesia and
normal left ventricular geometry. (AVI 6992 kb)
Additional file 3: Clip 3. Exam performed after 6 months. Normal left
ventricular geometry and function is restored. (MPEG 1612 kb)
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